You are here

  • Home
  • Archive
  • Volume 4, Issue 2
  • Correction: Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial

https://doi.org/10.1136/rmdopen-2018-000723corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD Open 2018;4:e000723. doi: 10.1136/rmdopen-2018-000723corr1

    The authors noticed a potential data inconsistency in the published version. The statement regarding the tuberculosis needs to be updated in the first paragraph of the ‘Safety’ sub-section under the ‘Results’ section (page 4).

    The corrected information on tuberculosis is: No new cases of tuberculosis, and noreactivation of latent tuberculosis were reported.